EX-99.3 4 a2234513zex-99_3.htm EX-99.3

Exhibit 99.3

 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

Contents

 

Independent Auditors’ Report

1

 

 

Consolidated Financial Statements:

 

 

 

Consolidated Statements of Financial Position

2

 

 

Consolidated Statements of Operations and Comprehensive Loss

3

 

 

Consolidated Statements of Changes in Equity

4

 

 

Consolidated Statements of Cash Flows

5

 

 

Notes to Consolidated Financial Statements

6-39

 



 

Independent Auditors’ Report

 

To the Shareholders of Cronos Group Inc. (formerly PharmaCan Capital Corp.):

 

We have audited the accompanying consolidated financial statements of Cronos Group Inc. (formerly PharmaCan Capital Corp.) which comprise the consolidated statements of financial position as at December 31, 2016 and 2015, and the consolidated statements of operations and comprehensive loss, changes in equity, and cash flows for the years then ended, and a summary of significant accounting policies and other explanatory information.

 

Management’s Responsibility for the Consolidated Financial Statements

 

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

 

Auditors’ Responsibility

 

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

 

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

 

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

 

Opinion

 

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Cronos Group Inc. (formerly PharmaCan Capital Corp.) as at December 31, 2016 and 2015, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

 

Emphasis of Matter

 

Without modifying our opinion, we draw attention to Note 2(b) to the consolidated financial statements which highlights the existence of a material uncertainty relating to conditions that cast significant doubt on Cronos Group Inc.’s (formerly PharmaCan Capital Corp.) ability to continue as a going concern.

 

 

/s/ MNP LLP

 

 

Mississauga, Ontario

Chartered Professional Accountants

April 30, 2017

Licensed Public Accountants

 

 


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Consolidated Statements of Financial Position

As at December 31, 2016 and December 31, 2015

 

 

 

Notes

 

2016

 

2015

 

Assets

 

 

 

 

 

 

 

Current

 

 

 

 

 

 

 

Cash

 

 

 

$

3,464,208

 

$

1,127,340

 

Accounts receivable

 

 

 

107,166

 

 

Prepaids and other receivables

 

 

 

503,155

 

97,745

 

Biological assets

 

7

 

1,794,740

 

 

Inventory

 

7

 

1,908,486

 

 

Loans receivable

 

8

 

308,833

 

 

 

 

 

 

8,086,588

 

1,225,085

 

Equity investment

 

9

 

2,565,412

 

2,404,615

 

Other investments

 

10

 

5,127,258

 

6,391,034

 

Property, plant and equipment

 

11

 

14,122,288

 

2,699,886

 

Goodwill

 

6

 

1,792,000

 

392,000

 

Other intangible assets

 

6

 

11,207,050

 

1,611,226

 

 

 

 

 

$

42,900,596

 

$

14,723,846

 

Liabilities

 

 

 

 

 

 

 

Current

 

 

 

 

 

 

 

Trade payables and other liabilities

 

18

 

$

1,175,600

 

$

1,061,991

 

Purchase price liability

 

5

 

2,590,367

 

 

Promissory note payable

 

12

 

 

950,000

 

Convertible loans payable

 

13

 

 

115,000

 

Deposit payable

 

14

 

 

200,000

 

Mortgage payable

 

15(b)

 

4,000,000

 

 

 

 

 

 

7,765,967

 

2,326,991

 

Mortgage payable

 

15(a)

 

 

500,000

 

Deferred income tax liability

 

21

 

1,457,000

 

195,000

 

 

 

 

 

9,222,967

 

3,021,991

 

Shareholders’ Equity

 

 

 

 

 

 

 

Share capital

 

16(a)

 

33,590,324

 

14,799,821

 

Warrants

 

16(b)

 

3,982,895

 

1,328,882

 

Contributed surplus

 

17

 

735,489

 

598,650

 

Accumulated deficit

 

 

 

(6,215,569

)

(5,025,498

)

Accumulated other comprehensive income

 

 

 

1,584,490

 

 

 

 

 

 

33,677,629

 

11,701,855

 

 

 

 

 

$

42,900,596

 

$

14,723,846

 

Going concern

 

2(b)

 

 

 

 

 

Commitments and contingencies

 

19

 

 

 

 

 

Subsequent events

 

26

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements

 

Approved on behalf of the Board of Directors:

 

“Michael Gorenstein”

 

“Michael Krestell”

Director

 

Director

 

2



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Consolidated Statements of Operations and Comprehensive Loss

Years ended December 31, 2016 and December 31, 2015

 

 

 

Notes

 

2016

 

2015

 

Product sales

 

 

 

$

554,203

 

$

 

Cost of revenue

 

 

 

 

 

 

 

Inventory expensed to cost of sales

 

 

 

383,626

 

 

Production costs

 

 

 

356,417

 

181,190

 

Loss (gain) on revaluation of biological assets

 

7

 

(2,178,810

)

20,000

 

 

 

 

 

(1,438,767

)

201,190

 

Gross margin, net of revaluation of biological assets

 

 

 

1,992,970

 

(201,190

)

Investment income

 

 

 

 

 

 

 

Share of income (loss) from equity accounted investment

 

9

 

162,951

 

(477,107

)

Interest income from loans receivable

 

8

 

6,617

 

41,589

 

Recovery of (impairment loss on) loans receivable

 

8

 

725,150

 

(698,292

)

Impairment loss on available-for-sale investments

 

10

 

 

(750,000

)

Gain (loss) on revaluation of other investments

 

10

 

(310,276

)

4,590,321

 

Income from non-refundable deposits

 

14

 

 

185,000

 

Other income

 

 

 

27,212

 

 

 

 

 

 

611,654

 

2,891,511

 

Expenses

 

 

 

 

 

 

 

Salary and benefits

 

 

 

826,053

 

335,783

 

Stock-based compensation

 

17(c)

 

306,817

 

 

General and administration

 

 

 

2,608,804

 

1,609,578

 

Financing fees

 

12

 

 

325,170

 

Interest expense

 

15

 

238,275

 

91,303

 

Depreciation

 

 

 

382,746

 

113,321

 

 

 

 

 

4,362,695

 

2,475,155

 

Income (loss) before income taxes

 

 

 

(1,758,071

)

215,166

 

Income tax recovery

 

21

 

(568,000

)

(171,000

)

Net income (loss)

 

 

 

$

(1,190,071

)

$

386,166

 

Gain on revaluation of other investments, net of taxes

 

10, 21

 

1,584,490

 

 

Total comprehensive income

 

 

 

$

394,419

 

$

386,166

 

Weighted average number of outstanding shares, basic

 

 

 

78,248,192

 

36,411,626

 

Basic earnings (loss) per share

 

 

 

$

(0.02

)

$

0.01

 

Weighted average number of outstanding shares, diluted

 

20

 

78,248,192

 

43,694,412

 

Diluted earnings (loss) per share

 

20

 

$

(0.02

)

$

0.01

 

 

The accompanying notes are an integral part of these consolidated financial statements

 

3


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Consolidated Statements of Changes in Equity

Years ended December 31, 2016 and December 31, 2015

 

 

 

Notes

 

Number of
shares

 

Share
capital

 

Warrants

 

Contributed
surplus

 

Accumulated
deficit

 

Accumulated
other
comprehensive
income

 

Total

 

Balance at January 1, 2015

 

 

 

34,786,562

 

$

13,586,129

 

$

368,650

 

$

728,650

 

$

(5,411,664

)

$

 

$

9,271,765

 

Shares issued

 

12

 

200,000

 

100,000

 

 

 

 

 

100,000

 

Shares repurchased

 

16(a)

 

(426,780

)

(170,000

)

 

(130,000

)

 

 

(300,000

)

Warrants exercised

 

16(b)

 

53,345

 

29,340

 

(16,537

)

 

 

 

12,803

 

Shares issued via private placement

 

16(a)

 

7,892,454

 

1,219,107

 

1,011,920

 

 

 

 

2,231,027

 

Warrants exercised - November 16, 2015

 

 

 

113,390

 

62,365

 

(35,151

)

 

 

 

27,214

 

Share issuance costs

 

 

 

 

(27,120

)

 

 

 

 

 

(27,120

)

Net income

 

 

 

 

 

 

 

386,166

 

 

386,166

 

Balance at December 31, 2015

 

 

 

42,618,971

 

$

14,799,821

 

$

1,328,882

 

$

598,650

 

$

(5,025,498

)

$

 

$

11,701,855

 

Shares issued

 

16(a,b)

 

75,289,565

 

18,096,364

 

2,832,029

 

 

 

 

20,928,393

 

Options issued

 

17(a)

 

 

 

 

178,391

 

 

 

178,391

 

Options exercised

 

17(a)

 

402,788

 

145,304

 

 

(41,552

)

 

 

103,752

 

Warrants exercised

 

16(b)

 

2,264,424

 

595,548

 

(178,016

)

 

 

 

417,532

 

Conversion of convertible loans payable

 

13

 

1,150,000

 

115,000

 

 

 

 

 

115,000

 

Share issuance costs

 

 

 

 

(161,713

)

 

 

 

 

(161,713

)

Net loss

 

 

 

 

 

 

 

(1,190,071

)

 

(1,190,071

)

Other comprehensive income

 

 

 

 

 

 

 

 

1,584,490

 

1,584,490

 

Balance at December 31, 2016

 

 

 

121,725,748

 

$

33,590,324

 

$

3,982,895

 

$

735,489

 

$

(6,215,569

)

$

1,584,490

 

$

33,677,629

 

 

The accompanying notes are an integral part of these consolidated financial statements

 

4


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Statements of Cash Flows

Years ended December 31, 2016 and December 31, 2015

 

 

 

Notes

 

2016

 

2015

 

Operating activities

 

 

 

 

 

 

 

Net income (loss)

 

 

 

$

(1,190,071

)

$

386,166

 

Items not affecting cash:

 

 

 

 

 

 

 

Impairment loss on (recovery of) loans receivable

 

 

 

(725,150

)

698,292

 

Share of loss (income) from equity accounted investment

 

9

 

(162,951

)

477,107

 

Impairment loss on available-for-sale investments

 

 

 

 

750,000

 

Deferred financing fees

 

12

 

 

325,170

 

Depreciation

 

 

 

382,746

 

113,321

 

Other

 

 

 

 

25,001

 

Deferred income tax recovery

 

21

 

(568,000

)

(171,000

)

Loss (gain) on revaluation of other investments

 

10

 

310,276

 

(4,590,321

)

Stock-based compensation

 

17(c)

 

306,817

 

 

 

 

 

 

(1,646,333

)

(1,986,264

)

Net changes in non-cash working capital:

 

 

 

 

 

 

 

Increase in prepaids and other receivables

 

 

 

(376,410

)

(51,511

)

Increase in inventory

 

 

 

(714,069

)

 

Decrease (increase) in biological assets

 

 

 

(929,198

)

20,000

 

Increase in accrued interest receivable

 

 

 

(6,617

)

(32,005

)

Decrease in accounts receivable

 

 

 

(56,519

)

 

Increase (decrease) in accounts payable and accrued expenses

 

 

 

(2,746,463

)

472,296

 

Increase in deposit payable

 

 

 

 

200,000

 

Cash flows used in operating activities

 

 

 

(6,475,609

)

(1,377,484

)

Investing activities

 

 

 

 

 

 

 

Cash acquired from Peace

 

5

 

109,443

 

 

Advances of loans receivable to Peace prior to acquisition

 

 

 

(771,898

)

(40,000

)

Receipts of loans receivable

 

8

 

422,934

 

90,000

 

Purchase of property, plant and equipment

 

11

 

(1,523,213

)

(1,509,460

)

Acquisition of Peace Natural Projects

 

5

 

(6,247,543

)

 

Dividends received from equity accounted investment

 

9

 

2,154

 

 

Cash flows used in investing activities

 

 

 

(8,008,123

)

(1,459,460

)

Financing activities

 

 

 

 

 

 

 

Proceeds from (repayment of) mortgage payable

 

15

 

(500,000

)

500,000

 

Proceeds from exercise of warrants

 

16(b)

 

417,532

 

40,017

 

Proceeds from issuance of warrants

 

16(b)

 

2,832,029

 

 

Proceeds from exercise of options

 

17(a)

 

103,752

 

 

Share repurchase

 

16(a)

 

 

(300,000

)

Repayment of deposit payable

 

14

 

(200,000

)

 

Proceeds from (repayment of) promissory note payable

 

12

 

(950,000

)

750,000

 

Repayments of loans and interest

 

 

 

(2,688,938

)

 

Debt issuance cost

 

 

 

 

(25,170

)

Proceeds from share issuance

 

16(a)

 

17,967,938

 

2,231,027

 

Share issuance costs

 

 

 

(161,713

)

(27,120

)

Cash flows provided by financing activities

 

 

 

16,820,600

 

3,168,754

 

Net change in cash

 

 

 

2,336,868

 

331,810

 

Cash - beginning of year

 

 

 

1,127,340

 

795,530

 

Cash - end of year

 

 

 

$

3,464,208

 

$

1,127,340

 

Supplemental cash flow information

 

 

 

 

 

 

 

Interest received

 

 

 

$

47,934

 

$

 

Interest paid

 

 

 

$

294,401

 

$

37,500

 

 

The accompanying notes are an integral part of these consolidated financial statements

 

5


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

1.                   Nature of business

 

Cronos Group Inc., formerly PharmaCan Capital Corp. (“Cronos” or the “Company”), was incorporated as 2339498 Ontario Inc. under the Business Corporations Act (Ontario) on August 21, 2012, changed its name on October 18, 2012 to Searchtech Ventures Inc. (“Searchtech”) and was classified as a Capital Pool Company as defined pursuant to Policy 2.4 of the TSX Venture Exchange (“TSX-V”). Cronos is a publicly traded corporation, with its head office located at 76 Stafford Street, Suite 302, Toronto, Ontario, M6J 2S1. The Company’s common shares are listed on TSX-V under the trading symbol “MJN”.

 

On December 10, 2014, the Company closed its Qualifying Transaction (the “Transaction”) with Hortican Inc. (“Hortican”), a company whose business model is to invest in medical marijuana companies in Canada, pursuant to which the shareholders of Hortican completed a reverse takeover of the Company. Immediately prior to the completion of the Transaction, the Company changed its name to PharmaCan Capital Corp. and consolidated its shares on a one for seven (1:7) basis. Following these changes, Hortican amalgamated with 8996741 Canada Inc., a wholly owned subsidiary of the Company formed solely for the purpose of facilitating the Transaction. Pursuant to the amalgamation, the Company indirectly acquired all of the issued and outstanding shares of Hortican and issued post-consolidation shares of the Company on the basis of approximately 2.1339 post-consolidation shares for each one of Hortican’s shares. Hortican warrants, stock options, and convertible debentures are also exchangeable at the same conversion ratio, and the exercise price for such securities is divided by the conversion ratio.

 

Effective upon the closing of the Transaction, the financial year end of the Company was changed from March 31 of each year to December 31 of each year to align the financial years of the Company to that of Hortican.

 

For the purposes of accounting for the Transaction, Hortican is considered the acquirer and the Company, the acquiree. Accordingly, the consolidated financial statements are in the name of Cronos Group Inc. (formerly PharmaCan Capital Corp.), however they are a continuation of the financial statements of Hortican, which was incorporated under the Business Corporations Act (Ontario) on January 17, 2013. The Company began rebranding itself as Cronos Group Inc. on October 6, 2016. Subsequent to year-end, the Company finalized its name change to Cronos Group Inc. on February 27, 2017.

 

In the Zone Produce Ltd. (“In the Zone”) was incorporated under the Business Corporations Act (British Columbia) on March 15, 2013. In the Zone is a licensed producer of medical cannabis pursuant to the provisions of the Access to Cannabis for Medical Purposes Regulation and the Controlled Drugs and Substances Act and its Regulations. Health Canada issued the license to In the Zone on February 26, 2014. In the Zone was acquired by Hortican on November 5, 2014.

 

Peace Natural Projects Inc. (“Peace”) was incorporated under the Business Corporations Act on November 21, 2012. Peace is a licensed producer and seller of medical cannabis pursuant to the provisions of the Access to Cannabis for Medical Purposes Regulation and the Controlled Drugs and Substances Act and its Regulations. Health Canada issued the license to Peace on October 31, 2013. Peace was acquired by Hortican on September 6, 2016. Additional information on the transaction is disclosed in Note 5.

 

6



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

2.                   Basis of presentation

 

(a)              Basis of consolidation

 

These consolidated financial statements include the accounts of Cronos Group Inc. (formerly Pharmacan Capital Corp.), and its wholly owned subsidiaries, Hortican Inc., In the Zone Produce Ltd., and Peace Naturals Project Inc. All intercompany transactions, balances, revenues and expenses have been eliminated. The Company applies the acquisition method to account for business combinations in accordance with IFRS 3. Acquisition related costs are expensed as incurred.

 

(b)              Going concern

 

These consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company’s ability to continue in the normal course of operations is dependent on its ability to raise equity financing or through the sale of its investments at amounts favourable to the Company, and on the ability of its subsidiaries to successfully renew their licenses to produce and sell medical cannabis. There are no assurances that the Company will be successful in achieving these goals. These circumstances cast significant doubt on the Company’s ability to continue as going concern and ultimately on the appropriateness of the use of the accounting principles applicable to a going concern. These consolidated financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations.

 

(c)               Statement of compliance

 

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

 

These consolidated financial statements were approved by the Board of Directors on April 30, 2017.

 

(d)              Basis of measurement

 

Apart from certain assets and liabilities measured at fair value as required under certain IFRSs, the consolidated financial statements have been presented and prepared on the basis of historical cost.

 

(e)               Functional and presentation currency

 

These consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and all subsidiaries.

 

(f)                Estimates and critical judgments by management

 

The preparation of these consolidated financial statements in conformity with International Financial Reporting Standards requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the current period. These estimates are reviewed periodically and adjustments are made to income as appropriate in the year they become known. Items for which actual results may differ materially from these estimates are described in the following section.

 

7



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

2.                   Basis of presentation (continued)

 

(f)                  Estimates and critical judgments by management (continued)

 

(i)                  Warrants and options

 

Warrants and options are initially recognized at fair value, based on the application of the Black-Scholes option pricing model. This pricing model requires management to make various assumptions and estimates which are susceptible to uncertainty, including the volatility of the share price, expected dividend yield and expected risk-free interest rate.

 

(ii)               Useful lives of property, plant and equipment

 

Depreciation of property, plant and equipment is dependent upon estimates of useful lives, which are determined through the exercise of judgement. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of the assets.

 

(iii)            Impairment of cash-generating units and goodwill

 

The impairment test for cash generating units (“CGUs”) to which goodwill is allocated is based on the value in use of the CGU, determined in accordance with the expected cash flow approach. The calculation is based primarily on assumptions used to estimate future cash flows, the cash flow growth rate and the discount rate used.

 

(iv)             Impairment of long-lived assets

 

Long-lived assets, including equipment and intangible assets are reviewed for impairment at each statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or group of assets (CGU). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.

 

(v)                Fair value of financial assets available-for-sale

 

Financial assets available for sale consist of privately and publicly held investments. Determination of the fair values of privately held investments requires the Company to make various assumptions about the future prospects of the investees, the economic, legal, and political environment in which the investees operate, and the ability of the investees to obtain financing to support their operations. As a result, any value estimated may not be realized or realizable, and the values may differ from values that would be realized if a ready market existed.

 

The determination of fair value of the Company’s privately held investments is subject to inherent limitations. Financial information for private companies may not be available, or may be unreliable. Use of the valuation approach described below involves uncertainties and management judgments, and any value estimated from these techniques may not be realized or realizable.

 

8



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

2.                   Basis of presentation (continued)

 

(f)                Estimates and critical judgments by management (continued)

 

(v)              Fair value of financial assets available-for-sale (continued)

 

The Company’s management considers specific information about the investee companies, trends in general market conditions, and the share performance of similar publicly traded companies when valuing the Company’s privately held investments.

 

The absence of the occurrence of any of the following events, any significant change in trends in general market conditions, or any significant change in share performance of comparable publicly traded companies generally indicates that the fair value of the privately held investments has not materially changed.

 

Management considers the following factors to indicate a change in the fair value, or impairment of, a privately held investment, and may adjust the value if:

 

a. there has been significant subsequent equity financing provided by outside investors at a value which differs from the current recorded value of the investee company, in which case the fair value of the investment is adjusted to equal the value at which that financing took place;

 

b. there have been significant corporate, political, legal, or operating events affecting the investee company such that, management believes they will have a material impact on the investee company’s prospects and therefore its fair value. In these circumstances, the adjustment to fair value of the investment will be based on management’s judgment;

 

c. the investee company is placed into receivership or bankruptcy;

 

d. based on financial information received from the investee company, it is evident that the investee company is unlikely to be able to continue as a going concern;

 

e. receipt or denial by the investee company of medical marijuana licenses from Health Canada, which allow the investee company to initiate or continue operations; and

 

f. management changes by the investee company that the Company’s management believes will have an impact on the investee company’s ability to achieve its objectives and build value for shareholders.

 

(vi)         Income taxes

 

Income taxes and tax exposures recognized in the consolidated financial statements reflect management’s best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

 

In addition, when the Company incurs losses that cannot be associated with current or past profits, it assesses the probability of taxable profits being available in the future based on its budgeted forecasts. These forecasts are adjusted to take account of certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate the sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

 

9



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

2.                   Basis of presentation (continued)

 

(v)              Fair value of financial assets available for sale (continued)

 

(vii)      Biological assets

 

Biological assets, consisting of cannabis plants, are measured at fair value less costs to sell. At the point of harvest, the biological assets are transferred to inventory at fair value less costs to sell, as a result, critical estimates related to the valuation of biological assets are also applicable to inventory.

 

Determining the fair value less costs to sell requires the Company to make assumptions about the expected future yield from the cannabis plants, the value associated with each stage of the plants’ growth cycle, estimated selling price, costs to convert harvested cannabis to finished goods, and costs to sell. The Company’s estimates, are, by their nature, subject to change. Gains or losses arising from changes in these estimates will be reflected in the fair value less costs to sell, and is included in the results of operations for the year.

 

3.                   Significant accounting policies

 

The principal accounting policies applied to the preparation of these consolidated financial statements are set out below:

 

(a)              Financial instruments

 

The Company aggregates its financial instruments into classes based on their nature and characteristics. Management determines the classification when the instruments are initially recognized, which is normally the date of the transaction.

 

All financial assets except those measured at fair value through profit or loss or available-for-sale are subject to review for impairment annually and written down when there is evidence of impairment based on specific criteria.

 

The Company’s accounting policy for each category is as follows:

 

(i)                  Fair-value through profit or loss

 

Financial instruments classified as fair value through profit and loss are reported at fair value at each reporting date, and any change in fair value is recognized in the statement of operations in the period during which the change occurs. In these financial statements, cash and investment in warrants of AbCann Medicinals Inc. (Note 10) have been classified as fair value through profit and loss.

 

(ii)               Available-for-sale

 

Financial instruments classified as available-for-sale are initially recorded at the fair value at the time of acquisition, represented by the transaction price. Thereafter, at each reporting date, the fair value may be adjusted using one or more of the valuation indicators. Gains and losses as a result of the valuations are recorded in other comprehensive income, unless they are other than temporary, and transaction costs are expensed as incurred. In these financial statements, investments in the shares of AbCann Medicinals Inc., The Hydropothecary Corporation, Vert Medical - Green Medical Inc., Canopy Growth Corporation, and Evergreen Medicinal Supply Inc. (Note 10) have been classified as available-for-sale. Prior to the acquisition of Peace, the Company’s investment in Peace was also classified as available-for-sale.

 

10



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

3.                     Significant accounting policies (continued)

 

(iii)            Held-to-maturity

 

Financial instruments classified as held-to-maturity are financial assets with fixed or determinable payments and fixed maturities that the Company’s management has the positive intention and ability to hold to maturity. These assets are initially recorded at fair value and subsequently carried at amortized cost, using the effective interest method. Transaction costs are included in the amount initially recognized. There are no financial instruments that are classified in this category.

 

(iv)           Loans and receivables and other financial liabilities

 

Financial instruments classified as loans and receivables and other financial liabilities are carried at amortized cost using the effective interest method. Transaction costs are expensed as incurred. In these financial statements, loans receivable and accounts receivable have been classified as loans and receivables. Trade payables and other liabilities, promissory note payable, deposit payable, convertible loans payable, mortgage payable and purchase price liability have been classified as other financial liabilities.

 

(b)              Equity accounted investments

 

Investees in which the Company exercises significant influence are accounted for using the equity method. Significant influence is the power to participate in the financial and operating policy decisions of the investee but does not have control over those policies.

 

Significant influence is presumed if the Company holds between 20% and 50% of the voting rights, unless evidence exists to the contrary. Equity accounting involves the Company recording its share of the investee’s net income and equity. The Company’s interest in an investee is initially recorded at cost and is subsequently adjusted for the Company’s share of changes in net assets of the investee, less any impairment in the value of individual investments. Where the Company transacts with an investee, unrealized profits and losses are eliminated to the extent of the Company’s interest in that investee.

 

(c)               Biological assets

 

The Company measures biological assets, consisting of medical cannabis plants, at fair value less costs to sell. Agricultural produce, consisting of medical cannabis, is measured at fair value less costs to sell at the point of harvest, which becomes the basis for the cost of finished goods inventory after harvest.

 

Gains and losses arising from changes in fair values less cost to sell during the period are included in the results of operations of the related period.

 

(d)              Inventory

 

Inventory of finished goods is transferred from biological assets at fair value less costs to sell at the point of harvest, which becomes the deemed cost. Subsequent to the harvest, additional costs incurred to bring the inventory to the point it is available for sale are capitalized to the cost of the inventory to the extent that the cost is below the net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and estimated variable costs to sell. Inventory of raw materials and consumables are measured at cost.

 

11



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

3.                   Significant accounting policies (continued)

 

(e)               Other intangible assets

 

The Health Canada licenses purchased through the business acquisition of In the Zone and through the business acquisition of the Peace Naturals Project Inc. (Note 5) are intangible assets which may be renewed indefinitely. As such, these intangible assets have indefinite useful lives and are not amortized, but are systematically tested for impairment annually in the fourth quarter or earlier if there is an indication of impairment. Inability to renew the license, or a lack of production are some of the indicators of impairment monitored by management.

 

(f)                Property, plant and equipment

 

Property, plant, and equipment are stated at cost less accumulated depreciation. They are depreciated on the basis of their useful lives using the following methods and rates:

 

 

 

Method

 

Rate

 

Building structures

 

straight-line

 

15 to 20 years

 

Furniture and equipment

 

straight-line

 

5 years

 

Computer equipment

 

straight-line

 

3 years

 

Fencing

 

straight-line

 

10 years

 

Security equipment

 

straight-line

 

5 years

 

Road

 

straight-line

 

25 years

 

Production equipment

 

straight-line

 

7 years

 

Leasehold improvements

 

straight-line

 

5 to 10 years

 

Vehicle

 

double-declining

 

30%

 

Software

 

double-declining

 

50%

 

 

An asset’s residual value, useful life and depreciation method are reviewed at each financial year end and adjusted if appropriate. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components).

 

Construction in progress at year-end has not been depreciated to date. The asset will be depreciated when the asset is available for use.

 

(g)               Convertible loans payable

 

The proceeds received on the issue of the Company’s convertible debt are allocated into their liability and equity components. The amount initially attributed to the debt component equals the discounted cash flows using a market rate of interest that would be payable on a similar debt instrument that does not include an option to convert. Subsequently, the debt component is accounted as a financial liability measured at amortized cost until extinguished on conversion or maturity of the bond. The remainder of the proceeds is allocated to the conversion option and is recognized in the “Convertible debt option reserve” within the shareholders’ equity, net of income tax effects. For convertible debt with a demand feature, the discounted cash flows are assumed to equal the proceeds of the loan.

 

(h)              Provisions

 

In accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets, provision for risks and expenses are recognized for probable outflows of resources that can be estimated and that result from present obligations resulting from past events. In the case where a potential obligation resulting from past events exists, but where occurrence of the outflow of resources is not probable or the estimate is not reliable, these contingent liabilities are disclosed in off-balance sheet commitments and litigation. The provisions are measured based on management’s best estimates of outcomes on the basis of facts known at the reporting date.

 

12


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

3.                   Significant accounting policies (continued)

 

(i)                  Share capital

 

Share capital is presented at the value of the shares issued. Costs related to the issuance of shares are reported in equity, net of tax, as deduction of the issuance proceeds.

 

(j)                 Revenue recognition

 

Revenue from the sale of finished goods is recognized when the Company has transferred the risks and rewards of ownership to the buyer and collection is reasonably assured. Risks and rewards of ownership are considered to be transferred upon shipment.

 

(k)              Foreign exchange translation

 

The financial statements of the Company are presented in Canadian dollars, which is the functional currency. Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. At each reporting date, foreign currency denominated monetary assets and liabilities are translated at year-end exchange rates. Exchange differences arising from the transactions are recorded in profit or loss for the period. Exchange differences arising from operating transactions are recorded in operating profit for the period; exchange differences related to financing transactions are recognized in finance income or in equity.

 

(l)                  Research and development

 

Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and use or sell the asset. Other development expenditures are recognized in profit and loss as incurred. To date, no development costs have been capitalized.

 

(m)          Income taxes

 

The Company accounts for its income taxes using the deferred tax assets and liabilities method. Deferred income tax assets and liabilities are determined based on the difference between the carrying amount and the tax basis of the assets and liabilities. Any change in the net amount of deferred income tax assets and liabilities is included in profit or loss or equity. Deferred income tax assets and liabilities are determined based on enacted or substantively enacted tax rates and laws which are expected to apply to taxable profit for the years in which the assets and liabilities will be recovered or settled. Deferred income tax assets are recognized when it is probable they will be realized. Deferred tax assets and liabilities are not discounted.

 

(n)              Share-based compensation

 

Where equity instruments are granted to employees, the fair value of the options at the date of grant is charged to the statement of operations over the vesting period. Performance vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each reporting date. For equity instruments granted to employees which vest immediately, they are recorded at the fair value of the equity instrument at the date granted.

 

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to the statement of operations over the remaining vesting period.

 

13



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

3.                   Significant accounting policies (continued)

 

(n)              Share-based compensation (continued)

 

Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received in the statement of operations. Options or warrants granted related to the issuance of shares are recorded as a reduction of share capital. When the value of goods or services received in exchange for the share-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model.

 

All equity-settled share-based payments are reflected in contributed surplus, until exercised. Upon exercise, shares are issued from treasury and the amount reflected in contributed surplus is credited to share capital, adjusted for any consideration paid.

 

Where a grant of options is cancelled or settled during the vesting period, excluding forfeitures when vesting conditions are not satisfied, the Company immediately accounts for the cancellation as an acceleration of vesting and recognizes the amount that otherwise would have been recognized for services received over the remainder of the vesting period. Any payment made to the employee on the cancellation is accounted for as the repurchase of an equity interest except to the extent the payment exceeds the fair value of the equity instrument granted, measured at the repurchase date. Any such excess is recognized as an expense.

 

(o)              Earnings per share

 

The Company presents basic and diluted earnings per share data for its common shares. Basic earnings per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all potentially dilutive common shares, which comprise convertible loans payable, warrants and share options.

 

4.                   New and revised standards and interpretations issued but not yet effective

 

(a)              IFRS 9 FINANCIAL INSTRUMENTS

 

IFRS 9 addresses classification and measurement of financial assets and replaces the multiple category and measurement models in IAS 39 for debt instruments with a new mixed measurement model having only two categories: amortized cost and fair value through profit and loss. IFRS 9 also replaces the models for measuring equity instruments and such instruments are either recognized at fair value through profit and loss or at fair value through other comprehensive income. The effective date of this standard is January 1, 2018. The Company will adopt this new standard as of its effective date. The Company is currently analyzing the possible impact of this Standard on its consolidated financial statements.

 

14



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

4.                   New and revised standards and interpretations issued but not yet effective (continued)

 

(b)              IFRS 15 REVENUE FROM CONTRACTS WITH CUSTOMERS

 

IFRS 15 was issued by IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. IFRS 15 becomes effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. The Company will adopt this new standard as of its effective date. The Company is currently analyzing the possible impact of this Standard on its consolidated financial statements.

 

(c)               AMENDMENTS TO IAS 7

 

IAS 7 amendments include additional disclosures to enable users of the financial statements to evaluate changes in liabilities arising from financing activities, including changes arising from cash flows and non-cash changes. These amendments become effective for annual periods beginning on or after January 1, 2017. The Company will adopt the amendments as of the effective date. The Company is currently analyzing the possible impact of the amendments on its consolidated financial statements.

 

(d)              IFRS 16 LEASES

 

IFRS 16 was issued in January 2016 and replaces the previous guidance on leases. This standard provides a single recognition and measurement model to be applied to leases, with required recognition of assets and liabilities for most leases. This standard is effective for annual periods beginning on or after January 1, 2019, with early adoption permitted if the Company is also applying IFRS 15, Revenue from Contracts with Customers. The Company will adopt this new standard as of its effective date. The Company is currently evaluating the impact of the adoption of this new standard on its consolidated financial statements.

 

(e)               AMENDMENTS TO IAS 12

 

IAS 12 Income Taxes amendments include: (a) unrealized losses on debt instruments measured at fair value and measured at cost for tax purposes give rise to a deductible temporary difference regardless of whether the debt instrument’s holder expects to recover the carrying amount of the debt instrument by sale or by use; (b) the carrying amount of an asset does not limit the estimation of probable future taxable profits; (c) estimates for future taxable profits exclude tax deductions resulting from the reversal of deductible temporary differences; and (d) an entity assesses a deferred tax asset in combination with other deferred tax assets. Where tax law restricts the utilisation of tax losses, an entity would assess a deferred tax asset in combination with other deferred tax assets of the same type. These amendments become effective for annual periods beginning on or after January 1, 2017. The Company will adopt this new standard as of its effective date. The Company is currently analyzing the possible impact of the amendments on its consolidated financial statements.

 

15



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

5.                   Acquisition of Peace Naturals Project

 

On September 6, 2016, the Company acquired all of the remaining issued and outstanding shares of Peace Naturals Project Inc. (“Peace”), a company headquartered in Stayner, Ontario. Consideration for the acquisition included $6,247,543 in cash and $2,590,367 (approximately 30%) to be paid, once all conditions of the agreement are settled. The conditions were based on the passage of time to ensure there were no additional liabilities identified (Note 26(n)). As of the acquisition date, the Company owns 100% of the outstanding shares of Peace. As the Company previously held shares of Peace, the acquisition is considered a step acquisition and resulted in a loss due to fair value remeasurement. The preliminary purchase price allocation for this acquisition is shown below:

 

Fair value of consideration transferred:

 

 

 

Cash

 

$

6,247,543

 

Liability

 

2,590,367

 

 

 

8,837,910

 

Fair value of previously held interest:

 

 

 

Fair value of previously held interest immediately before acquisition

 

3,314,960

 

Loss due to fair value remeasurement at acquisition date

 

(346,970

)

 

 

2,967,990

 

 

 

$

11,805,900

 

Fair value of net assets acquired:

 

 

 

Cash

 

$

109,443

 

Accounts receivable

 

50,647

 

Prepaid and deposits

 

29,000

 

Inventory

 

1,194,417

 

Biological assets

 

865,542

 

Property and equipment

 

10,281,935

 

Goodwill

 

1,400,000

 

Other intangible assets (i)

 

9,595,824

 

Accounts payable and accrued liabilities

 

(2,860,072

)

Loans payable

 

(7,460,836

)

Deferred tax liability

 

(1,400,000

)

 

 

$

11,805,900

 

 


(i)                  Other intangible assets are expected to include a Health Canada license.

 

The amount of net income and comprehensive income of Peace since the acquisition date included in these consolidated financial statements was $724,239.

 

Net loss and comprehensive net loss for the Company would have been lower by approximately $283,980 if the acquisition had taken place on January 1, 2016.

 

Due to the complexities in identifying certain intangible assets, such as licenses and intellectual property, and assigning fair values, the Company has yet to finalize its assessment of the purchase price allocation. The allocation of the consideration paid will be adjusted once a valuation of certain intangible assets has been finalized. Management expects to complete the assessment within the next fiscal year.

 

16



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

6.                   Intangible assets

 

 

 

Balance at

 

 

 

Balance at

 

 

 

As at

 

 

 

January 1,

 

 

 

December 31,

 

Additions

 

December 31,

 

Goodwill

 

2015

 

Additions

 

2015

 

(Note 5)

 

2016

 

In the Zone

 

$

392,000

 

$

 

$

392,000

 

$

 

$

392,000

 

Peace (Note 5)

 

 

 

 

1,400,000

 

1,400,000

 

 

 

$

392,000

 

$

 

$

392,000

 

$

1,400,000

 

$

1,792,000

 

 

 

 

Balance at

 

 

 

Balance at

 

 

 

As at

 

 

 

January 1,

 

 

 

December 31,

 

Additions

 

December 31,

 

Other intangible assets

 

2015

 

Additions

 

2015

 

(Note 5)

 

2016

 

In the Zone Health Canada License

 

$

1,611,226

 

$

 

$

1,611,226

 

$

 

$

1,611,226

 

Peace (Note 5)

 

 

 

 

9,595,824

 

9,595,824

 

 

 

$

1,611,226

 

$

 

$

1,611,226

 

$

9,595,824

 

$

11,207,050

 

 

7.                   Biological assets and inventory

 

The Company’s biological assets consist of medical cannabis plants. The changes in the carrying amount of the biological assets are as follows:

 

 

 

2016

 

2015

 

Carrying amount - beginning of year

 

$

 

$

20,000

 

Changes in fair value of biological assets

 

2,178,810

 

(20,000

)

Increase due to acquisition of Peace (Note 5)

 

865,542

 

 

Transferred to inventory upon harvest

 

(1,249,612

)

 

 

 

 

 

 

 

Carrying amount - end of year

 

$

1,794,740

 

$

 

 

The Company estimates the harvest yields for the plants varies at different stages of growth. As of December 31, 2016, it is expected that the Company’s biological assets will yield approximately 213 kg of medical cannabis (December 31, 2015 - Nil). As at December 31, 2016, the Company held 236 kg of finished goods and 0.298 kg of seeds in raw material, and has 2,558 plants that are biological assets.

 

The valuation of the medical cannabis plants was completed using the Company’s internal model. Significant assumptions used in determining the fair value of medical cannabis plants include: (a) stage of plant growth, (b) wastage of plants in their various stages, (c) sale price less cost to sell, and (d) harvest yield. Management believes that differences arising from the sensitivity of the inputs are not material.

 

17



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

7.                   Biological assets and inventory (continued)

 

Inventory consists of the following:

 

 

 

2016

 

2015

 

Finished goods

 

$

1,502,064

 

$

 

Raw materials

 

193,880

 

 

Supplies and consumables

 

212,542

 

 

 

 

$

1,908,486

 

$

 

 

8.                   Loans receivable

 

 

 

2016

 

2015

 

(a) Loan receivable from Evergreen Medicinal Supply Inc. (“Evergreen”)

 

$

264,750

 

$

264,750

 

(b) Loan receivable from Vert/Green Medical Inc.

 

375,000

 

375,000

 

 

 

639,750

 

639,750

 

Add: Accrued interest

 

92,017

 

58,542

 

 

 

731,767

 

698,292

 

Less: Impairment loss

 

 

(698,292

)

Less: Principal and interest received

 

(422,934

)

 

Loans receivable

 

$

308,833

 

$

 

 


(a)              During the year ended December 31, 2015, the Company recognized an impairment loss on the loan amount of $264,750 and the accrued interest of approximately $14,500.

 

During the year ended December 31, 2016, the Company revised the estimates of the recoverability of the loan due to updated and favourable operational conditions, and wrote up the loan to the initial amount of $264,750 plus accrued interest of approximately $37,500. The loan was due on demand, bearing interest at 8% per year, calculated and payable annually in arrears.

 

(b)              During the year ended December 31, 2015, the Company recognized an impairment loss on the loan of $375,000 and the accrued interest of approximately $44,000.

 

During the year ended December 31, 2016, the full amount of the loan plus accrued interest was repaid and the entire amount was recovered. The loan was due on demand, and bore interest at 8% per year, calculated and payable semi-annually in arrears.

 

18



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

9.                   Equity investment

 

 

 

2016

 

2015

 

(a) Whistler Medical Marijuana Company

 

$

2,565,412

 

$

2,404,615

 

(b) Peace Naturals Project Inc. (“Peace”)

 

 

 

 

 

$

2,565,412

 

$

2,404,615

 

 


(a)         As at December 31, 2016, the investment represents approximately 21.5% (December 31, 2015 - 21.5%) ownership in Whistler Medical Marijuana Company, incorporated in Canada. Whistler Medical Marijuana Company is a licensed producer and seller of medical marijuana with operations in British Columbia, Canada. The investment is accounted for using the equity method.

 

Summarized financial information of Whistler Medical Marijuana Company is as follows:

 

 

 

2016

 

2015

 

Current assets

 

$

2,233,175

 

$

1,458,776

 

Non-current assets

 

3,855,394

 

2,640,886

 

Current liabilities

 

1,649,191

 

1,272,576

 

Non-current liabilities

 

865,000

 

 

 

 

 

2016

 

2015

 

Revenue

 

$

2,817,080

 

$

934,118

 

Income (loss) from continuing operations

 

756,638

 

(54,501

)

 

Reconciliation of the carrying amount of the investment is as follows:

 

 

 

2016

 

2015

 

Balance - beginning of year

 

$

2,404,615

 

$

2,416,352

 

Company’s share of dividends paid

 

(2,154

)

 

Company’s share of income (loss)

 

162,951

 

(11,737

)

Balance - end of year

 

$

2,565,412

 

$

2,404,615

 

 

(b)         As at September 30, 2015, the investment represented 26.1% ownership in Peace and was accounted for using the equity method.

 

During the fourth quarter of 2015, the Company determined that it was unable to exercise significant influence over this investee, and therefore, only nine months of the Company’s share of the investee’s income was included in the balance of the investment before the reclassification to available for sale. This investment was included in other investments at December 31, 2015 and was reported at fair value, determined using an exit price of approximately $7 per share, based on a market participant’s proposed sale of its shares of Peace, resulting in an unrealized gain of $4,590,321 included in net income. In 2016, to the date of acquisition (Note 5), the investment was classified as available-for-sale (Note 10) and changes in fair value were recorded through other comprehensive income.

 

19


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

9. Equity investment (continued)

 

Summarized financial information of Peace Naturals Project Inc. is as follows:

 

 

 

Period from Jan

 

 

 

1 to September

 

 

 

30, 2015

 

Revenue

 

$

1,120,837

 

Loss from continuing operations

 

(1,757,206

)

 

Reconciliation of the carrying amount of the investment is as follows:

 

 

 

2015

 

Balance - beginning of year

 

$

515,993

 

Company’s share of loss

 

(465,370

)

Transfer to other investments

 

(50,623

)

Balance - end of year

 

$

 

 

10.            Other investments

 

Other investments consist of investments in common shares of several companies in the medicinal marijuana industry. These shares, with the exception of Canopy Growth Corporation, do not have a quoted price in an active market, do not have a readily available market, and as a result do not have a reliably measurable fair value.

 

 

 

2016

 

2015

 

Available-for-sale investments

 

 

 

 

 

The Hydropothecary Corporation (i)

 

$

412,502

 

$

250,000

 

Vert Medical - Green Medical Inc. (ii)

 

 

 

Canopy Growth Corporation (ii)

 

337,010

 

 

AbCann Medicinals Inc. (iii)

 

3,073,172

 

1,500,090

 

Peace Naturals Project Inc. (Note 9(b))

 

 

4,640,944

 

Evergreen Medicinal Supply Inc. (iv)

 

300,000

 

 

 

 

$

4,122,684

 

$

6,391,034

 

Fair-value through profit and loss investment

 

 

 

 

 

AbCann Medicinals Inc. - share warrants (v)

 

$

1,004,574

 

$

806,000

 

Less: Deferred gain on acquisition of warrants (v)

 

 

(806,000

)

 

 

$

1,004,574

 

$

 

 

 

$

5,127,258

 

$

6,391,034

 

 

20



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

10.            Other investments (continued)

 


(i)                  During the year ended December 31, 2016, the Company received bonus shares pursuant to the original agreement, for $Nil consideration. The transaction price is less than the fair value at the date of receipt, and the gain of $25,000 on initial recognition was initially deferred as the fair value was based on other than level 1 inputs. During the year, the deferred gain was taken into income as factors that market participants would consider when valuing the shares have changed. The fair value of all of the shares held as at December 31, 2016 is estimated to be $412,502, based on the share price of the financing that took place in December 2016.

 

(ii)               At December 31, 2015, the Company’s investment in Vert Medical - Green Medical Inc. (“Vert”) of $450,000 was considered to be impaired. Management’s assessment was that it was not probable that Vert would obtain a Health Canada license or additional financing in the foreseeable future, and therefore, the investment was written down to $Nil.

 

During the year ended December 31, 2016, Canopy Growth Corporation (“Canopy”) acquired all of the outstanding shares of Vert. In exchange for shares in Vert, Canopy issued the former Vert shareholders, shares of Canopy. The fair value of the Canopy shares at the date of the transaction of $258,104 determined the proceeds on derecognition of the Vert shares. Since the gain was realized, it was recorded as income. The fair value of the Canopy shares at the date of the transaction was also the deemed cost of the Canopy shares, which were then revalued to fair value at December 31, 2016, with the subsequent gain being recorded as other comprehensive income.

 

(iii)            During the year ended December 31, 2016, the Company received bonus shares pursuant to the original agreement, for $Nil consideration. The transaction price was less than the fair value at the date of receipt, and the gain of $75,000 on initial recognition was initially deferred as the fair value was based on other than level 1 inputs. During the year, the deferred gain was taken into income as factors that market participants would consider when valuing the shares changed. The fair value of all of the shares held as at December 31, 2016 was estimated to be $3,073,172, after considering valuation of the investee’s peer group.

 

(iv)           At December 31, 2015, the Company’s investment in Evergreen of $300,000 was considered to be impaired. Management’s assessment was that it was not probable that Evergreen would obtain a Health Canada license or additional financing in the foreseeable future, and therefore, the investment was written down to $Nil.

 

During the year ended December 31, 2016, management revised their estimate of the fair value of the investment back to its original value, based on management’s assessment of the likelihood Evergreen would receive a license to produce and sell medical marijuana. The gain on the revaluation of the investment has been recognized as other comprehensive income.

 

(v)              During the year ended December 31, 2016, the Company received bonus warrants pursuant to the original agreement, for $Nil consideration. The transaction price was less than the fair value at the date of receipt, and the gain of $24,000 on initial recognition was initially deferred as the fair value was based on other than level 1 inputs. As at December 31, 2015, there was also a deferred gain from the original warrants received in 2014 of $806,700. During the year ended December 31, 2016, the deferred gain on the bonus warrants and the original warrants was taken into income as factors that market participants would consider when valuing the warrants have changed. As at December 31, 2016, the fair value of the warrants was estimated using the Black-Scholes option pricing model with the following assumptions: risk free rate: 0.60 - 0.73%; volatility: 65%; expected life: 0.70 - 1.7 years; and dividend yield: Nil%. The fair value of all of the warrants as at December 31, 2016 is estimated to be $1,004,574, after considering valuation of the investee’s peer group.

 

21



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

10.            Other investments (continued)

 

The gains recognized upon the increase in fair value on other investments is as follows:

 

 

 

2016

 

2015

 

Peace Naturals Project Inc.

 

$

(1,325,984

)

$

4,590,321

 

Peace Naturals Project Inc. - immediately before acquisition (Note 5)

 

(346,970

)

 

The Hydropothecary Corporation (i)

 

25,000

 

 

Vert Medical - Green Medical Inc. (ii)

 

258,104

 

 

AbCann Medicinals Inc. (iii)

 

75,000

 

 

AbCann Medicinals Inc. - share warrants (v)

 

1,004,574

 

 

Gain (loss) recognized through profit-and-loss

 

$

(310,276

)

$

4,590,321

 

 

 

 

2016

 

2015

 

The Hydropothecary Corporation (i)

 

$

137,502

 

$

 

Canopy Growth Corporation (ii)

 

78,906

 

 

AbCann Medicinals Inc. (iii)

 

1,498,082

 

 

Evergreen Medicinal Supply Inc. (iv)

 

300,000

 

 

Gain recognized through other comprehensive income

 

$

2,014,490

 

$

 

 

11. Property, plant and equipment

 

 

 

Balance at

 

 

 

 

 

As at

 

 

 

January 1,

 

 

 

Acquisition

 

December 31,

 

Cost

 

2016

 

Additions

 

(Note 5)

 

2016

 

Land

 

$

210,000

 

$

623,177

 

$

725,000

 

$

1,558,177

 

Building structures

 

824,127

 

62,135

 

1,875,000

 

2,761,262

 

Vehicle

 

 

 

31,430

 

31,430

 

Furniture and equipment

 

26,658

 

 

5,048

 

31,706

 

Computer equipment

 

28,859

 

 

18,575

 

47,434

 

Software

 

 

37,939

 

2,648

 

40,587

 

Fencing

 

3,249

 

 

 

3,249

 

Security equipment

 

179,898

 

291,478

 

 

471,376

 

Production equipment

 

72,656

 

408,371

 

1,624,234

 

2,105,261

 

Road

 

137,376

 

 

 

137,376

 

Leasehold improvements

 

1,363,014

 

65,951

 

 

1,428,965

 

Construction in progress

 

 

34,162

 

6,000,000

 

6,034,162

 

 

 

$

2,845,837

 

$

1,523,213

 

$

10,281,935

 

$

14,650,985

 

 

22



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

11. Property, plant and equipment (continued)

 

 

 

Balance at

 

 

 

As at

 

 

 

January 1,

 

 

 

December 31,

 

Accumulated depreciation

 

2016

 

Additions

 

2016

 

Building structures

 

$

62,569

 

$

57,572

 

$

120,141

 

Vehicle

 

 

3,929

 

3,929

 

Furniture and equipment

 

7,998

 

5,720

 

13,718

 

Computer equipment

 

12,111

 

13,601

 

25,712

 

Software

 

 

10,147

 

10,147

 

Fencing

 

650

 

325

 

975

 

Security equipment

 

7,915

 

50,680

 

58,595

 

Production equipment

 

14,455

 

88,979

 

103,434

 

Road

 

181

 

5,496

 

5,677

 

Leasehold improvements

 

40,072

 

146,297

 

186,369

 

 

 

$

145,951

 

$

382,746

 

$

528,697

 

Net book value

 

$

2,699,886

 

 

 

$

14,122,288

 

 

 

 

Balance at

 

 

 

As at

 

 

 

January 1,

 

 

 

December 31,

 

Cost

 

2015

 

Additions

 

2015

 

Land

 

$

210,000

 

$

 

$

210,000

 

Building structures

 

823,405

 

722

 

824,127

 

Road

 

 

137,376

 

137,376

 

Furniture and equipment

 

26,658

 

 

26,658

 

Computer equipment

 

20,359

 

8,500

 

28,859

 

Fencing

 

2,978

 

271

 

3,249

 

Security equipment

 

18,945

 

160,953

 

179,898

 

Production equipment

 

52,504

 

20,152

 

72,656

 

Leasehold improvements

 

181,528

 

1,181,486

 

1,363,014

 

 

 

$

1,336,377

 

$

1,509,460

 

$

2,845,837

 

 

 

 

Balance at

 

 

 

As at

 

 

 

January 1,

 

 

 

December 31,

 

Accumulated depreciation

 

2015

 

Additions

 

2015

 

Building structures

 

$

20,423

 

$

42,146

 

$

62,569

 

Road

 

 

181

 

181

 

Furniture and equipment

 

2,666

 

5,332

 

7,998

 

Computer equipment

 

2,048

 

10,063

 

12,111

 

Fencing

 

54

 

596

 

650

 

Security equipment

 

440

 

7,475

 

7,915

 

Production equipment

 

867

 

13,588

 

14,455

 

Leasehold improvements

 

6,132

 

33,940

 

40,072

 

 

 

$

32,630

 

$

113,321

 

$

145,951

 

Net book value

 

$

1,303,747

 

 

 

$

2,699,886

 

 

23



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

12.            Promissory note payable

 

The Company issued a promissory note in the amount of $750,000 on June 26, 2015, bearing interest at 15% per annum with an interest free period for the first 60 days. Interest was payable monthly from and after the interest free period.

 

The loan was due on the earliest of: (a) the Company receiving other financing in excess of $750,000 (b) the date of completion of the sale of shares of In the Zone Produce Ltd., (c) June 26, 2016. Since the Company raised financing through private placements exceeding the $750,000 during the fiscal year ended December 31, 2015, this promissory note became due on demand as at December 31, 2015.

 

Upon execution of this note, $15,000 in cash as well as 200,000 common shares of the Company was paid as an initial structuring fee. The common shares were valued at $100,000 based on the share price at the issuance date. Additionally, the Company agreed to pay $200,000 on August 26, 2015 as an additional structuring fee if the principal was not repaid in full within the first 60 days. The Company failed to repay the principal within 60 days and as a result, the structuring fee was added to the principal of the promissory note.

 

The promissory note payable was repaid in full on May 17, 2016. The payment of $1,054,762 included principal of $950,000, and accrued interest.

 

 

 

2016

 

2015

 

Face value of promissory note

 

$

 

$

750,000

 

Add: Additional structuring fee

 

 

200,000

 

 

 

$

 

$

950,000

 

 

The financing fees associated with this transaction are as follows:

 

 

 

2016

 

2015

 

Initial structuring fee

 

$

 

$

115,000

 

Additional structuring fee

 

 

200,000

 

Legal fees

 

 

10,170

 

 

 

$

 

$

325,170

 

 

13. Convertible loans payable

 

 

 

2016

 

2015

 

Loan payable to an Officer of the Company

 

$

 

$

100,000

 

Loan payable to a related corporation (i)

 

 

7,500

 

Loan payable to a Director of the Company

 

 

7,500

 

 

 

$

 

$

115,000

 

 


(i)                  The loan was payable to a corporation that is controlled by a former officer of the Company.

 

The loans were payable to a former officer and a former director of the Company. The loans were non-interest bearing, unsecured and due on demand. The loans were convertible into common shares of the Company at the option of the holder at a price of $0.07 per share, however due to TSX-V requirements and agreement among the associated parties, the loans may not be converted at a price below $0.10. As such, the conversion price while listed was $0.10 per share. The fair market value of these loans was allocated to the debt component.

 

The convertible loans were converted and accordingly discharged on July 22, 2016, resulting in the issuance of 1,150,000 common shares at a value of $115,000.

 

24



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

14.            Deposit payable

 

During 2015, the Company received $450,000 related to a letter of intent signed by a potential purchaser of In the Zone, of which $200,000 was refundable. Since the purchaser did not proceed, $200,000 was refundable, and an additional $65,000 was repayable as a reimbursement of costs to the purchaser, which was included in accounts payable and accrued liabilities as at December 31, 2015. During 2015, $185,000 was taken into income, and $265,000 was refunded during the year ended December 31, 2016.

 

15.            Mortgage payable

 

(a)              On January 15, 2015, the Company obtained a mortgage for $500,000, secured by the land and building structures used in the production of cannabis, with a carrying amount of $960,290 as at December 31, 2015. The mortgage terms consisted of interest at 7.5% per annum, with monthly interest-only payments of $3,125, based on a twenty-five year amortization period. The terms of the mortgage included an original maturity date of January 15, 2020. The full balance of the mortgage and accrued interest, plus an additional $15,000 early settlement fee, was repaid on June 6, 2016.

 

(b)              On September 6, 2016, the Company obtained a mortgage in connection with the acquisition of Peace (Note 5) with a principal balance of $4,000,000. The mortgage bears interest at 12% per annum compounded and payable monthly. The mortgage matures on June 1, 2017. The mortgage is secured by a first charge on Peace’s property as well as a first ranking security interest charging all the personal property of Peace and each covenantor in the amount of the loan.

 

16.            Share capital and reserves

 

(a)              Share capital

 

(i)                  Common Shares

 

The Company is authorized to issue an unlimited number of common shares.

 

The holders of the common shares are entitled to receive dividends which may be declared from time to time, and are entitled to one vote per share at meetings of the Company. All shares are ranked equally with regards to the Company’s residual assets.

 

During the year ended December 31, 2015, the Company issued units through a private placement. Each unit was comprised of one common share and one common share purchase warrant. The Company received $2,231,027 in exchange for 7,892,454 units. The consideration was proportionately allocated on a fair value basis between shares and warrants.

 

During the year ended December 31, 2015, the Company repurchased 426,780 shares from the original founders of In the Zone, in exchange for $300,000 in cash. The shares were originally recorded for $170,000, and therefore, the premium of $130,000 paid was recorded to contributed capital. Of these shares, 298,746 (2015 - 341,424) remain in escrow, and will be cancelled immediately upon release.

 

During the year ended December 31, 2016, 75,289,565 common shares were issued in private placements, 32,432,425 of which were issued as units, where the holder received one common share and one common share purchase warrant. Total consideration raised through private placements in 2016 was $20,928,393, of which $128,426 was recognized in lieu of compensation (Note 17). The consideration was proportionately allocated on a fair value basis between shares and warrants. The share issuance cost associated with these issuances was $161,713.

 

25



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

16.            Share capital and reserves (continued)

 

(a)              Share capital (continued)

 

(i)                  Common Shares (continued)

 

As at December 31, 2016, 3,233,992 of the Company’s shares are held in escrow (December 31, 2015 - 5,719,214). The release of these shares is subject to regulatory approval.

 

(ii)               Special Shares

 

The Company is authorized to issue an unlimited number of special shares, issuable in series.

 

The special shares may be issued in one or more series and the directors are authorized to fix the number of shares in each series and to determine the designation, right, privileges, restrictions and conditions attached to the shares in each series. No special shares have been issued since the Company’s inception.

 

(b)              Warrants

 

The following is a summary of changes in warrants for the periods from January 1, 2015 to December 31, 2015 and from December 31, 2015 to December 31, 2016:

 

 

 

Number of

 

 

 

 

 

Warrants

 

Amount

 

Balance at January 1, 2015

 

8,069,703

 

$

368,650

 

Exercise of warrants - February 27, 2015 (i)

 

(53,345

)

(16,537

)

Issuance of warrants - October 2015 (Note 16(a)(i)

 

7,892,454

 

1,011,920

 

Exercise of warrants - November 16, 2015 (ii)

 

(113,390

)

(35,151

)

Balance at December 31, 2015

 

15,795,422

 

$

1,328,882

 

Issuance of warrants - May 2016 (iii)

 

32,432,425

 

2,832,029

 

Exercise of warrants - July 2016 (iv)

 

(55,000

)

 

Exercise of warrants - August 2016 (v)

 

(100,000

)

(14,527

)

Exercise of warrants - October 2016 (vi)

 

(661,505

)

(96,099

)

Exercise of warrants - November 2016 (vii and viii)

 

(883,320

)

(59,640

)

Exercise of warrants - December 2016 (ix and x)

 

(564,599

)

(7,750

)

Expiry of warrants

 

(78,251

)

 

Balance at December 31, 2016

 

45,885,172

 

$

3,982,895

 

 


(i)      53,345 warrants were exercised in exchange for $12,803 in cash. These warrants were granted on October 1, 2013, and had an exercise price of $0.24.

 

(ii)     113,390 warrants were exercised in exchange for $27,214 in cash. These warrants were granted on October 1, 2013 and had an exercise price of $0.24.

 

(iii)    32,432,425 units were issued in two private placements. Each unit consisted of one common share and one common share purchase warrant. These warrants had an exercise price of $0.245.

 

(iv)    55,000 warrants were exercised in exchange for $4,400 in cash. These warrants were granted on January 18, 2013, and had an exercise price of $0.08.

 

(v)     100,000 warrants were exercised in exchange for $24,000 in cash. These warrants were granted on October 1, 2013, and had an exercise price of $0.24.

 

26


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

16.    Share capital and reserves (continued)

 

(b)     Warrants (continued)

 

(vi)           661,505 warrants were exercised in exchange for $158,761 in cash. These warrants were granted on October 1, 2013, and had an exercise price of $0.24.

 

(vii)        460,877 warrants were exercised in exchange for $142,872 in cash. These warrants were granted on October 28, 2015, and had an exercise price of $0.31.

 

(viii)     422,443 warrants were exercised in exchange for $33,796 in cash. These warrants were granted on January 18, 2013, and had an exercise price of $0.08.

 

(ix)           53,347 warrants were exercised in exchange for $12,803 in cash. These warrants were granted on December 18, 2013, and had an exercise price of $0.24.

 

(x)              511,252 warrants were exercised in exchange for $40,900 in cash. These warrants were granted on January 18, 2013, and had an exercise price of $0.08.

 

As at December 31, 2016, the Company has outstanding warrants as follows:

 

 

 

Number of

 

 

 

 

 

Grant date

 

warrants

 

Exercise price

 

Expiry

 

January 18, 2013

 

5,626,398

 

$

0.08

 

18-Jan-18

 

January 30, 2014

 

394,772

 

0.70

 

30-Jan-17

 

October 8, 2015

 

5,242,031

 

0.31

 

8-Oct-20

 

October 23, 2015

 

1,478,245

 

0.31

 

23-Oct-20

 

October 28, 2015

 

711,301

 

0.31

 

28-Oct-20

 

May 13, 2016

 

10,810,812

 

0.245

 

13-May-21

 

May 27, 2016

 

21,621,613

 

0.245

 

27-May-21

 

 

 

45,885,172

 

$

0.24

 

 

 

 

17.    Share-based payments

 

(a)     Option Plan Details

 

The Company has an incentive Stock Option Plan (“the Plan”) under which non-transferrable options to purchase common shares of the Company may be granted to directors, officers, or service providers of the Company. The terms of the Plan provide that Directors have the right to grant options to acquire common shares of the Company at not less than the selling price of the shares on the day preceding the grant at varying terms. The maximum number of common shares reserved for issuance for options that may be granted under the Plan is 10% of the common shares outstanding. No amounts are paid or payable by the recipient on receipt of the option, and the options granted are not dependent on any performance-based criteria.

 

27



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

17.    Share-based payments (continued)

 

(a)     Option Plan Details (continued)

 

The following is a summary of the changes in options for the periods from January 1, 2015 to December 31, 2015 and from December 31, 2015 to December 31, 2016:

 

 

 

Number of

 

 

 

 

 

Options

 

Amount

 

Balance at January 1, 2015

 

1,648,574

 

$

598,650

 

Expiry of options (viii)

 

(38,571

)

 

Balance at January 1, 2016

 

1,610,003

 

$

598,650

 

Issuance of options - May 2016 (i)

 

157,850

 

5,928

 

Issuance of options - August 2016 (ii)

 

1,225,000

 

29,934

 

Issuance of options - October 2016 (iii)

 

3,618,500

 

114,065

 

Issuance of options - November 2016 (iv)

 

482,000

 

28,464

 

Exercise of options - August 2016 (v)

 

(213,390

)

(31,000

)

Exercise of options - August 2016 (vi)

 

(157,390

)

(5,902

)

Exercise of options - October 2016 (vii)

 

(32,008

)

(4,650

)

Expiry of options (viii)

 

(512,971

)

 

Balance at December 31, 2016

 

6,177,594

 

$

735,489

 

 


(i)                  During the year ended December 31, 2016, 157,850 options were issued to a former consultant and a former director of the Company. These options had an exercise price of $0.285.

 

(ii)               During the year ended December 31, 2016, 975,000 options were issued to key management of the Company and 250,000 were issued to various directors of the Company. These options had an exercise price of $0.50, and vest evenly over a 48 month period.

 

(iii)            During the year ended December 31, 2016, 1,687,500 options were issued to key management of the Company, 1,366,000 were issued to various directors of the Company, and 565,000 were issued to various employees of the Company. These options had an exercise price of $1.23, and vest evenly over a 48 month period.

 

(iv)           During the year ended December 31, 2016, 300,000 and 182,000 options were issued to consultants of the Company. These options had exercise prices of $1.50 and $1.84, and vest in May 2017 and evenly over a 48 month period, respectively.

 

(v)              During the year ended December 31, 2016, 213,390 options were exercised in exchange for $51,214 in cash. These options were granted on October 1, 2013, and had an exercise price of $0.24.

 

(vi)           During the year ended December 31, 2016, 157,390 options were exercised in exchange for $44,856 in cash. These options were granted on May 17 and 27, 2016, and had an exercise price of $0.285.

 

(vii)        During the year ended December 31, 2016, 32,008 options were exercised in exchange for $7,682 in cash. These options were granted on October 1, 2013, and had an exercise price of $0.24.

 

(viii)     During the year ended December 31, 2016, 512,971 (2015 - 38,571) options expired, which had a weighted average exercise price of $0.96 (2015 - $0.70).

 

The weighted average share price at the dates of exercise of options during the year ended December 31, 2016 was $0.52 (2015 - n/a as no options were exercised).

 

28



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

17.    Share-based payments (continued)

 

As at December 31, 2016, the Company had outstanding and exercisable options as follows:

 

 

 

 

 

Weighted

 

 

 

 

 

Number of

 

average

 

Weighted average remaining

 

Grant date

 

options

 

exercise price

 

contractual life (years)

 

January 30, 2014

 

32,009

 

$

0.70

 

0.08

 

August 5, 2014

 

213,390

 

1.15

 

0.59

 

September 19, 2014

 

106,695

 

1.15

 

0.72

 

December 17, 2014

 

500,000

 

1.15

 

0.96

 

August 5, 2016

 

1,225,000

 

0.50

 

4.60

 

October 6, 2016

 

3,618,500

 

1.23

 

4.77

 

November 16, 2016

 

300,000

 

1.50

 

1.37

 

November 21, 2016

 

182,000

 

1.84

 

4.88

 

Outstanding at December 31, 2016

 

6,177,594

 

$

1.10

 

4.03

 

Exercisable at December 31, 2016

 

1,209,646

 

$

1.09

 

1.96

 

 

As at December 31, 2016, the weighted average exercise price of options outstanding is $1.10 (2015 - $0.94). The weighted average exercise price of options exercisable is $1.09 (2015 - $0.94).

 

(b)     Fair Value of Options Issued During the Year

 

The fair value of the options was determined using the Black-Scholes option pricing model. The following inputs were used:

 

 

 

2016

 

2015

 

Share price at grant date

 

$0.19 - $1.77

 

n/a

 

Exercise price

 

$0.285 - $1.84

 

n/a

 

Risk free interest rate

 

0.54% - 0.67%

 

n/a

 

Expected life of options (years)

 

0.25 - 5

 

n/a

 

Expected annualized volatility

 

55% - 150%

 

n/a

 

Expected dividend yield

 

0%

 

n/a

 

Weighted average Black Scholes value at grant date

 

$0.43

 

n/a

 

 

During Q3 2016, management revised their estimate of the Company’s future volatility factor to 55%.

 

(c)     Expenses Arising from Share-based Payment Transactions

 

Total expenses arising from share-based payment transactions recognized during the year as part of stock-based compensation were $306,817 (2015 - $Nil), $128,426 of which was issued in shares to key management (Note 18(a)(i)).

 

29



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

18.    Related party transactions and balances

 

The following is a summary of the Company’s related party transactions during the year:

 

(a)     Key management compensation

 

Key management personnel are persons responsible for planning, directing and controlling activities of an entity, and include executive and non-executive directors. Compensation provided to key management is as follows:

 

 

 

2016

 

2015

 

Short-term employee benefits, including salaries and fees

 

$

264,029

 

$

238,614

 

Professional fees

 

171,097

 

68,985

 

Stock-based compensation (i)

 

207,816

 

 

 

 

$

642,942

 

$

307,599

 

 


(i)                  Stock-based compensation is comprised of $128,426 of shares issued in lieu of compensation, and $79,390 in stock options provided to key management of the Company. Refer to Note 17.

 

(b)              Purchase of shares and warrants

 

(i)                  On October 28, 2015, members of key management purchased 701,754 units of the Company’s private placement. Each unit is comprised of one share and one warrant, entitling the holder to purchase one common share at $0.31. The members of key management paid $200,000 for these units, which represented the fair value.

 

(ii)               On May 27, 2016, a board member purchased 810,810 units of the Company’s private placement. Each unit is comprised of one share and one share purchase warrant, entitling the holder to purchase one common share at $0.245. The board member paid approximately $150,000 for these units, which represents the fair value.

 

(iii)            On May 27, 2016, a shareholder with ownership interest exceeding 10%, purchased 4,665,187 units of the Company’s private placement. Each unit is comprised of one share and one share purchase warrant, entitling the holder to purchase one common share at $0.245. The shareholder paid approximately $863,000 for these units, which represents the fair value.

 

(c)               Issuance of options

 

(i)                  On August 5, 2016, 250,000 options were issued to directors of the Company. These options had an exercise price of $0.50. Share-based compensation expense of $6,109 was recognized for these options. Refer to Note 17.

 

(ii)               On October 6, 2016, 1,366,000 options were issued to directors of the Company. These options had an exercise price of $1.23. Share-based compensation expense of $43,060 was recognized for these options. Refer to Note 17.

 

As at December 31, 2016, there was a balance payable of $Nil to directors of the Company (2015 - $233,000) and a balance payable of $85,797 to members of key management (2015 - $Nil).

 

30



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

19.    Commitments and contingencies

 

(a)              The following is a summary of the Company’s operating lease obligations due in future fiscal years:

 

2017

 

$

20,400

 

2018

 

5,100

 

 

 

$

25,500

 

 

(b)              The Company owns approximately 6.25% of Evergreen Medicinal Supply Inc. (included in Other Investments). The Company subscribed for an additional 18.75% ownership at a cost of $900,000. The closing of this subscription is conditional and will occur in tranches, beginning no later than the date of confirmation by Health Canada of an inspection to assess the eligibility of Evergreen Medicinal Supply Inc. to obtain a license to produce and sell medical marijuana. (Note 26(g))

 

(c)               The following are related to Peace:

 

(i)                  Peace is subject to a claim for $12 million for damages related to the death of 12 cannabis plants held in its care, amounting to $1 million per plant. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend itself; accordingly, no provision for loss has been recognized.

 

(ii)               Peace is subject to a claim for $15 million for the non-closure of a share purchase agreement. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend itself; accordingly, no provision for loss has been recognized.

 

(iii)            Peace is subject to a claim for $125,000 related to warrants of the Company that were not issued as was originally agreed upon. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend itself; accordingly, no provision for loss has been recognized.

 

(iv)           Peace was subject to a claim for $50 million for damages related to unlawful interference with the plaintiff’s economic relations. Subsequent to year end, the claim was settled for a nominal amount without admission of liability.

 

20.    Earnings (loss) per share

 

Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators:

 

Numerators

 

2016

 

2015

 

Income (loss) attributable to common shareholders

 

$

(1,190,071

)

$

386,166

 

 

 

 

 

 

 

Income (loss) used in the computation of basic and diluted earnings per share

 

$

(1,190,071

)

$

386,166

 

 

Denominators

 

2016

 

2015

 

Weighted average number of common shares for computation of basic

 

78,248,192

 

36,411,626

 

Dilutive effect of convertible loans payable

 

 

1,642,857

 

Dilutive effect of warrants

 

 

5,570,910

 

Dilutive effect of options

 

 

69,018

 

Weighted average number of common shares for computation of diluted earnings per share

 

78,248,192

 

43,694,412

 

 

31



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

20.    Earnings (loss) per share (continued)

 

In 2016, all instruments were anti-dilutive. In 2015, 473,023 warrants with an exercise price of $0.70, 245,399 options with an exercise price of $0.70, and 1,119,205 options with an exercise price of $1.15 were anti-dilutive, and therefore, excluded from the calculation of diluted earnings per share.

 

21.    Income taxes

 

The components of the tax recovery include:

 

 

 

2016

 

2015

 

Current

 

$

 

$

 

Deferred

 

(568,000

)

(171,000

)

 

 

$

(568,000

)

$

(171,000

)

 

The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% (2015 - 26.5%) to the effective tax rate is as follows:

 

 

 

2016

 

2015

 

Income (loss) before income taxes

 

$

(1,758,071

)

$

215,166

 

Combined statutory tax rate

 

26.5

%

26.5

%

Theoretical tax expense (recovery)

 

(466,000

)

57,000

 

Non-deductible expenses:

 

 

 

 

 

Stock-based compensation

 

81,000

 

 

Effect of provincial tax rate difference

 

4,000

 

4,000

 

Other adjustments

 

 

(389,000

)

Changes in unrecognized deferred tax assets

 

(187,000

)

157,000

 

Income tax recovery

 

$

(568,000

)

$

(171,000

)

 

The components of deferred tax are summarized below. Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset.

 

 

 

2016

 

2015

 

Deferred tax assets

 

 

 

 

 

Non-capital losses carried forward

 

$

1,243,000

 

$

 

Farm losses carried forward

 

444,000

 

224,000

 

SR&ED

 

28,000

 

 

 

 

 

 

 

 

Deferred tax liabilities

 

 

 

 

 

Biological assets

 

(18,000

)

 

Inventory

 

(51,000

)

 

Property, plant and equipment

 

(141,000

)

 

License (i)

 

(2,962,000

)

(419,000

)

Net deferred tax liability

 

$

(1,457,000

)

$

(195,000

)

 

32


 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

21.            Income taxes (continued)

 


(i)             During 2015, the Company finalized its purchase price allocation on the acquisition of In the Zone, resulting in an additional deferred tax liability recorded as at the date of acquisition. The deferred tax liability was partially offset by deferred tax assets of In the Zone as at December 31, 2015, resulting in a deferred tax recovery recognized in the statement of operations for the year then ended. During 2016, the Company performed a purchase price allocation on the acquisition of Peace, resulting in an additional deferred tax liability recorded as at the date of acquisition. (Note 5)

 

Movement in the net deferred tax liability is provided below:

 

 

 

2016

 

2015

 

Balance - beginning of year

 

$

195,000

 

$

366,000

 

Recognized in income

 

(568,000

)

(171,000

)

Recognized in other comprehensive income

 

430,000

 

 

Recognized in goodwill

 

1,400,000

 

 

Balance - end of year

 

$

1,457,000

 

$

195,000

 

 

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences because it is not probable that future taxable profit will be available against which the Company can utilize the benefits therefrom.

 

 

 

2016

 

2015

 

Property, plant and equipment

 

$

(17,000

)

$

143,000

 

Equity accounted investments

 

24,000

 

712,000

 

Share and debt issuance costs (i)

 

288,000

 

1,219,000

 

Losses carried forward (ii)

 

1,728,000

 

2,522,000

 

Other investments

 

(695,000

)

(646,000

)

Net deferred tax asset not recognized

 

$

1,328,000

 

$

3,950,000

 

 

(i)                  Share and debt issuance costs will be fully amortized in 2021. The remaining deductible temporary differences may be carried forward indefinitely.

 

(ii)               For income tax purposes, the Company has losses carried forward from prior years which can be used to reduce future years’ taxable income. These losses expire as follows:

 

 

 

Non-capital &

 

 

 

farm losses

 

2032

 

$

536,000

 

2033

 

1,217,000

 

2034

 

4,138,000

 

2035

 

3,785,000

 

2036

 

3,245,000

 

 

 

$

12,921,000

 

 

33



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

22.                               Operating segment information

 

The Company is divided into two operating segments corresponding to the two primary business models. The first segment relates to pursuing equity investments into licensed medical marijuana producers in Canada, (“Investing Segment”). This segment derives revenue through increases in the value of the investments and through the Company’s share of income. The second segment relates to production and sale of medical cannabis through the wholly-owned subsidiaries, In the Zone and Peace (Note 5), (“Operating Segment”). Reporting by segment follows the same accounting policies as those used to prepare the consolidated financial statements.

 

The operating segments are presented in accordance with the same criteria used for the internal reporting prepared for the chief operating decision-makers responsible for allocating resources and assessing performance. Inter-segment transactions are recorded at the stated values as agreed to by the segments.

 

All of the Company’s assets are located in Canada.

 

For the year ended December 31, 2016:

 

 

 

Investing

 

Operating

 

Inter-segment

 

 

 

 

 

Segment

 

Segment

 

Elimination

 

2016

 

Statement of Operations

 

 

 

 

 

 

 

 

 

Product sales

 

$

 

$

554,203

 

$

 

$

554,203

 

Share of income from equity investment

 

162,951

 

 

 

162,951

 

Gain on revaluation of biological assets

 

 

2,178,810

 

 

2,178,810

 

Production costs

 

 

356,417

 

 

356,417

 

Inventory expensed as cost of sales

 

 

383,626

 

 

383,626

 

Recovery of loans receivable

 

725,150

 

 

 

725,150

 

Loss on revaluation of other investments

 

(310,276

)

 

 

(310,276

)

Intercompany revenue

 

436,953

 

 

(436,953

)

 

Stock-based compensation

 

306,817

 

 

 

306,817

 

Interest expense

 

84,247

 

349,870

 

(195,842

)

238,275

 

Depreciation

 

62,308

 

322,510

 

(2,072

)

382,746

 

Net income (loss)

 

$

(1,380,549

)

$

(379,077

)

$

569,555

 

$

(1,190,071

)

Statement of Financial Position

 

 

 

 

 

 

 

 

 

Total assets

 

$

59,045,684

 

$

16,428,686

 

$

(32,573,774

)

$

42,900,596

 

Total liabilities

 

24,557,988

 

17,576,687

 

(32,911,708

)

9,222,967

 

Shareholders’ equity

 

$

34,487,696

 

$

(1,148,001

)

$

337,934

 

$

33,677,629

 

Other information

 

 

 

 

 

 

 

 

 

Property, plant and equipment

 

$

1,085,188

 

$

10,871,776

 

$

2,165,324

 

$

14,122,288

 

Purchase of property, plant, and

 

 

 

 

 

 

 

 

 

equipment

 

 

1,496,220

 

26,993

 

1,523,213

 

 

34



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

22.                               Operating segment information (continued)

 

Reconciling items in the statement of operations include intercompany interest (approximately $187,000), management fees (approximately $150,000), and land lease costs (approximately $100,000). Reconciling items in the statement of financial position include the license and goodwill acquired on initial acquisition of In the Zone (approximately $1,900,000) and initial acquisition of Peace (approximately $11,000,000), the elimination of the investment in In the Zone (approximately $1,500,000) and of the investment in Peace (approximately $12,000,000), and the elimination of the intercompany loan balances (approximately $33,800,000).

 

For the year ended December 31, 2015:

 

 

 

 

 

 

 

Elimination of

 

 

 

 

 

Investing

 

Operating

 

inter-segment

 

 

 

 

 

Segment

 

Segment

 

accounts

 

2015

 

Statement of Operations

 

 

 

 

 

 

 

 

 

Share of loss from equity investments

 

$

477,107

 

$

 

$

 

$

477,107

 

Unrealized gain on investment

 

4,590,321

 

 

 

4,590,321

 

Intercompany revenue

 

304,722

 

 

(304,722

)

 

Interest revenue

 

41,589

 

 

 

41,589

 

Interest expense

 

90,533

 

5,970

 

(5,200

)

91,303

 

Depreciation

 

56,992

 

56,467

 

(138

)

113,321

 

Net income (loss)

 

$

910,121

 

$

(487,071

)

$

(36,884

)

$

386,166

 

 

 

 

 

 

 

 

 

 

 

Statement of Financial Position

 

 

 

 

 

 

 

 

 

Total assets

 

$

16,755,666

 

$

2,041,625

 

$

(4,073,445

)

$

14,723,846

 

Total liabilities

 

4,483,355

 

2,709,986

 

(4,171,350

)

3,021,991

 

Shareholders’ equity

 

$

12,272,311

 

$

(668,361

)

$

97,905

 

$

11,701,855

 

 

 

 

 

 

 

 

 

 

 

Other information

 

 

 

 

 

 

 

 

 

Property, plant and equipment

 

$

1,147,405

 

$

1,589,365

 

$

(36,884

)

$

2,699,886

 

Purchase of property, plant, and

 

153,966

 

1,392,515

 

(37,021

)

1,509,460

 

equipment

 

 

 

 

 

 

 

 

 

 

Reconciling items in the consolidated statement of operations include intercompany interest (approximately $42,000), management fees (approximately $162,000), and land lease costs (approximately $100,000). Reconciling items in the consolidated statement of financial position include the license acquired on initial acquisition of In the Zone (approximately $1,600,000), the elimination of the investment in In the Zone (approximately $1,500,000), and the elimination of the intercompany loan balances (approximately $4,200,000).

 

35



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

23.                               Financial instruments

 

(a)                                 Financial risks

 

(i)                                     Liquidity risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company’s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company’s management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. The Company’s funding is provided in the form of capital raised through the issuance of shares, loans, notes, and mortgages payable.

 

The following represents an analysis of the age of trade payables:

 

 

 

2016

 

2015

 

Current

 

$

146,848

 

$

628,145

 

Less than 30 days past billing date

 

149,892

 

14,832

 

31 to 60 days past billing date

 

33,049

 

301,406

 

61 to 90 days past billing date

 

15,992

 

2,453

 

Over 90 days past billing date

 

240,101

 

 

 

 

$

585,882

 

$

946,836

 

 

(ii)                                  Credit risk

 

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company is exposed to this risk through its loans receivable, and accounts receivable.

 

As at December 31, 2016, the value of its loans receivable was $308,833 (December 31, 2015 - $Nil) and the value of its accounts receivable was $107,166 (December 31, 2015 - $Nil). The Company is not significantly exposed to credit risk, as these receivables comprise 0.7% (December 31, 2015 - 0%) of the Company’s total assets.

 

(iii)                               Market risk

 

(1)                                 Price risk

 

Price risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to price risk in divesting its investments in private companies and unfavourable market conditions could result in dispositions of investments at less than favourable prices. Further, in the revaluation of securities classified as available-for-sale, this could result in significant write-downs of the Company’s investments, which would have an adverse impact on the Company’s financial position.

 

The Company manages price risk by having a portfolio of securities from multiple issuers, such that the Company is not singularly exposed to any one issuer. The Company also has set thresholds on purchases of investments over which the approval of the Board of Directors is required.

 

36



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

23.                               Financial instruments (continued)

 

(iii)                               Market risk (continued)

 

(2)                                 Concentration risk

 

Concentration risk is the risk that any single investment or group thereof, has the potential to materially affect the operating results of the Company. The Company is exposed to this risk as all of its investments are currently within the medical marijuana industry. As such, the Company’s financial results may be adversely affected by the unfavourable performance of those investments or the industry in which they operate.

 

It is management’s opinion that the Company is not subject to significant interest rate risk.

 

24.                               Fair value hierarchy

 

Assets recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

 

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities;

 

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and

 

Level 3 - valuation techniques using the inputs for the asset or liability that are not based on observable market data (unobservable inputs).

 

In these consolidated financial statements, classification of assets measured at fair value is as follows:

 

Level 1 - cash; other investments (Canopy)

 

Level 2 - warrants, options;

 

Level 3 - other investments (AbCann shares and warrants, Hydropothecary, Evergreen), biological assets.

 

During the year ended December 31, 2016, the Company invested in shares of Canopy (see Note 10), and since these are publicly traded, the valuation is classified as level 1. During the years ended December 31, 2015 and 2016, there were no transfers of amounts between Level 1 and Level 2 and 3.

 

25.                               Capital management

 

The Company considers its capital to be its equity. The Company’s objectives when managing its capital are to maintain sufficient capital base in order to meet its short-term obligations and at the same time preserve investors’ confidence required to sustain future investments.

 

37



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

26.            Subsequent events

 

(a)              Subsequent to year end, the $50 million claim against the Company was settled for a nominal amount without admission of liability.

 

(b)              Subsequent to the year end, the Company closed its previously announced bought deal offering pursuant to the filing of a short form prospectus, including the full exercise of the over-allotment option. A total of 7,705,000 common shares of the Company were sold at a price of $2.25 per Share for aggregate gross proceeds of $17,336,250.

 

(c)               The Company holds a 21.5% interest in Whistler Medical Marijuana Corp. (“WMMC”). Subsequent to the year end, the Company has decided to maintain its 21.5% equity position through an additional $1,075,800 investment to help support WMMC’s next phase of growth.

 

(d)              Subsequent to the year end, BFK Capital Corp. acquired all of the outstanding shares of Hydropothecary Corporation, and began trading as Hydropothecary Corporation, (TSX-V:THCX). As a result of this transaction, Hydropothecary Corporation executed a 6:1 stock split, and the fair value of the investment held by the Company at the date of the transaction was approximately $1M, based on the opening share price of $1.82 per share.

 

(e)               Subsequent to the year end, the Company’s wholly owned subsidiary, In the Zone Produce, received its license to sell dried marijuana and its renewal to produce dried marijuana from Health Canada.

 

(f)                Subsequent to the year end, the Company has granted options to subscribe to 3,299,000 common shares of the Company to certain of the Company’s employees and directors, in accordance with the Company’s stock option plan. The options are exercisable at a price of $3.14 per common share and shall expire at the earlier of 180 days of the death, disability or incapacity of the holder or five years after the date of issue.

 

(g)               Subsequent to the year end, the full amount of the loan plus accrued interest with Evergreen Medicinal Inc. was repaid. In addition, on March 16, 2017, Evergreen received a cultivation license under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”). As a result, the Company completed its subscription for a second tranche of shares of Evergreen for $100,000 and exercised its option to acquire an additional 5% of the equity of Evergreen for $500,000, for a total additional investment of $600,000. However, Evergreen, through its counsel, has indicated that the Company is not entitled to any interest in Evergreen and has rejected the payment. The Company filed a statement of claim in the Supreme Court of British Columbia and intends to vigorously pursue the enforcement of its rights to acquire equity in

 

(h)              Subsequent to the year end, 375,565 warrants were exercised at an exercise price of $0.70 per warrant, and correspondingly, 375,565 common shares were issued.

 

(i)                  Subsequent to the year end, 296,695 options were exercised at an exercise price of $1.15 per option, and correspondingly, 296,695 common shares were issued.

 

(j)                 Subsequent to the year end, 1,491,228 warrants were exercised at an exercise price of $0.31 per warrant, and correspondingly, 1,491,228 common shares were issued.

 

(k)              Subsequent to the year end, 1,042,263 warrants were exercised at an exercise price of $0.08 per warrant, and correspondingly, 1,042,264 common shares were issued.

 

38



 

Cronos Group Inc. (formerly PharmaCan Capital Corp.)

Notes to Consolidated Financial Statements

Years ended December 31, 2016 and December 31, 2015

 

26.            Subsequent events (continued)

 

(l)                  Subsequent to the year end, 32,009 options were exercised at an exercise price of $0.70 per option, and correspondingly, 32,009 common shares were issued.

 

(m)          Subsequent to the year end, 30,416 options were exercised at an exercise price of $1.23 per option, and correspondingly, 30,416 common shares were issued.

 

(n)              Subsequent to the year end, the conditions associated with the purchase price liability as part of the acquisition of Peace (Note 5) were met. Pursuant to the agreement, 50% of the liability was repaid, with the remaining 50% to be released at a later date.

 

39